UBS Reiterates Neutral Rating on Incyte (INCY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St set to open lower after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 116.93 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $116.93 | 52 Week High | $118.49 | |||
| Open | $116.93 | 52 Week Low | $55.00 | |||
| Day High | $116.93 | P/E | N/A | |||
| Day Low | $116.93 | EPS | $-0.56 | |||
| Volume | 10,282 | |||||
